These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36923472)

  • 1. Mapping the energy landscape of PROTAC-mediated protein-protein interactions.
    Villegas JA; Vaid TM; Johnson ME; Moore TW
    Comput Struct Biotechnol J; 2023; 21():1885-1892. PubMed ID: 36923472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes.
    Zaidman D; Prilusky J; London N
    J Chem Inf Model; 2020 Oct; 60(10):4894-4903. PubMed ID: 32976709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of Three-Body Problems and Protein-Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations.
    Li W; Zhang J; Guo L; Wang Q
    J Chem Inf Model; 2022 Feb; 62(3):523-532. PubMed ID: 35084845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Modeling of PROTAC-Mediated Ternary Complexes.
    Weng G; Li D; Kang Y; Hou T
    J Med Chem; 2021 Nov; 64(21):16271-16281. PubMed ID: 34709816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.
    Bai N; Miller SA; Andrianov GV; Yates M; Kirubakaran P; Karanicolas J
    J Chem Inf Model; 2021 Mar; 61(3):1368-1382. PubMed ID: 33625214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current strategies for the design of PROTAC linkers: a critical review.
    Troup RI; Fallan C; Baud MGJ
    Explor Target Antitumor Ther; 2020; 1(5):273-312. PubMed ID: 36046485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native mass spectrometry and gas-phase fragmentation provide rapid and in-depth topological characterization of a PROTAC ternary complex.
    Song JH; Wagner ND; Yan J; Li J; Huang RY; Balog AJ; Newitt JA; Chen G; Gross ML
    Cell Chem Biol; 2021 Oct; 28(10):1528-1538.e4. PubMed ID: 34081921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring and deciphering protein degradation pathways inside cells.
    Daniels DL; Riching KM; Urh M
    Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches for the rational design of PROTAC linkers.
    Zagidullin A; Milyukov V; Rizvanov A; Bulatov E
    Explor Target Antitumor Ther; 2020; 1(5):381-390. PubMed ID: 36046487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
    Hu Z; Crews CM
    Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linker-Dependent Folding Rationalizes PROTAC Cell Permeability.
    Poongavanam V; Atilaw Y; Siegel S; Giese A; Lehmann L; Meibom D; Erdelyi M; Kihlberg J
    J Med Chem; 2022 Oct; 65(19):13029-13040. PubMed ID: 36170570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy.
    Beveridge R; Kessler D; Rumpel K; Ettmayer P; Meinhart A; Clausen T
    ACS Cent Sci; 2020 Jul; 6(7):1223-1230. PubMed ID: 32724856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation
    Drummond ML; Henry A; Li H; Williams CI
    J Chem Inf Model; 2020 Oct; 60(10):5234-5254. PubMed ID: 32969649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex.
    Weerakoon D; Carbajo RJ; De Maria L; Tyrchan C; Zhao H
    J Chem Inf Model; 2022 Jan; 62(2):340-349. PubMed ID: 35018781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystallization of VHL-based PROTAC-induced ternary complexes.
    Wijaya AJ; Farnaby W; Ciulli A
    Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.